Vetoquinol has announced the launch of Rubenal®, a new product for use in renal health management for dogs and cats.
Normal kidney function is dependent upon normal nephron and interstitial tissue structure. When the balance of renal health is tipped, this structure can change and fibrous tissue can accumulate.
Simon Boulton, Rubenal®'s product manager said: "Rubenal® is the first palatable veterinary formulation of Rheum officinale available for use in both dogs and cats. It can be used as an aid to the maintenance of the normal renal fibrotic architecture."
The company has also produced a new guide to the management of chronic renal failure in dogs and cats: Chronic Kidney Disease: Addressing quality of life and life expectancy.
Simon said: "Vetoquinol is dedicated to supporting renal health and the guide is designed to illustrate factors which can affect both quality and quantity of life, including hyperphosphataemia, hypertension, proteinuria, azotaemia and fibrosis in renal disease."
The booklet contains guidelines on the appropriate management of these factors including a wall chart reference guide.
For more information about Rubenal, or a free copy of the guide, please contact your Vetoquinol representative or telephone 0800 1698197.
Centaur Services' veterinary wholesale business has been acquired by AHN International. Centaur was founded in 1964 by a group of veterinary surgeons who wanted to increase their buying power and the range of products available to them. Over the next 44 years the business, which was owned by its veterinary surgeon shareholders, grew to a turnover of nearly £140m. The company has recently completed a 3 year programme of modernisation making it one of the most technologically advanced wholesalers in Europe. In September 2007, Centaur Services announced its intention to list its shares on the Alternative Investments Market (AIM). These plans were initially postponed and finally cancelled when the Centaur shareholders accepted the offer from AHN. Paul Gerring, Centaur Services' Managing Director said: "There has been considerable consolidation in the veterinary market over recent years, particularly amongst manufacturers, and this partnership with AHN provides us with an increased presence in the market. Like Centaur, AHN is a vet-focussed business with plans to be active in the veterinary supply market on a European and global basis. We see plenty of exciting opportunities out there". AHN International was established to form the first global coalition of leading animal health wholesalers and distributors. With nearly 700 employees worldwide, AHN International is committed to presenting the veterinary surgeons with an advanced level of product and services. Headquartered in Raleigh, North Carolina, AHN International will actively build it's network of leading trading companies around the world through acquisitions and business associations.
The support pack features information on the role anaesthetic induction agents can play in the maintenance of anaesthesia to help veterinary surgeons provide appropriate care for their patients.
The pack includes a user guide to achieving the best outcome when using Alfaxan for the induction and maintenance of anaesthesia, a summary of peer-reviewed key clinical papers on the use of Alfaxan and how it can be used for the maintenance of anaesthesia, an article discussing the use of intravenous agents to maintain anaesthesia in the dog and cat, frequently asked questions and an Alfaxan dosage chart for CRI (Constant Rate Infusion) and intermittent bolus.
To download the pack, visit www.alfaxan.co.uk.
Richard Beckwith, country manager for Jurox (UK) Ltd. said: "We have received a significant increase in enquiries following the isoflurane supply issues.
"The new support pack will provide veterinary professionals with comprehensive information on Alfaxan to help practices develop options in providing appropriate anaesthesia for patients."
For more information, call Jurox customer services on 0800 500 3171, or e-mail: info@jurox.co.uk.
Elanco Companion Animal Health has launched Recuvyra 50mg/ml transdermal solution for dogs, the first transdermal fentanyl solution to be licensed for the control of postoperative pain associated with major orthopaedic and soft tissue surgery.
Recuvyra is a schedule two controlled drug which contains fentanyl, a pure μ-agonist synthetic opioid with a potency 100 times that of morphine1. Applied to the area between the shoulder blades by a needleless two-pronged adapter two to four hours prior to surgery, Elanco says Recuvyra provides at least four days of opioid analgesia, which is mainly due to the activation of the μ-opioid receptors inhibiting the perception of pain and the transmission of pain signals in the spinal cord and dorsal horn2.
Elanco says Recuvyra's unique formulation provides long-lasting analgesia by establishing a depot of fentanyl within the stratum corneum. The fentanyl in this depot undergoes passive diffusion down a concentration gradient, and is steadily released into the general circulation over a number of days.
Ed Whittle MA VetMB MRCVS, technical consultant at Elanco said: "Fentanyl is widely used in human health and its powerful analgesic properties are well known amongst veterinary surgeons1, 3, 4. Recuvyra is a ground-breaking veterinary product that will provide long-acting post-operative pain control in dogs while reducing the need for repeated, invasive administration of analgesics in the practice and improved client compliance and the potential for mutimodal analgesia once a dog returns home."
To ensure proper use of Recuvyra, Elanco has produced a mandatory online training programme for veterinary surgeons to complete before ordering the product. The brief online training module, which can be viewed at www.recuvyratraining.eu, features information on the presentation, correct preparation and administration of the product, and the safe handling of patients that have been treated with Recuvyra. Once veterinary surgeons are trained, it is their responsibility to train their staff on the in-practice use of Recuvyra and Elanco has produced a training presentation to help educate veterinary professionals about the product.
To support the launch of Recuvyra, Elanco has produced a dosing calculator, cage cards and client information sheet. For further information on Recuvyra, please contact your Elanco Companion Animal Health key account manager or email elancocah.uk@elanco.com.
References
Clare graduated from the University of Glasgow in 1991 and, following an internship at the University of Pennsylvania and general practice in Cambridgeshire, she completed a BSAVA/Petsavers Residency and was Staff Clinician in Neurology at the Royal Veterinary College.
Aged 26, she became the youngest ever Diplomate of the European College of Veterinary Neurology and three year later became a RCVS Specialist.
For 16 years, she operated a neurology and neurosurgery referral service at the Stone Lion Veterinary Hospital in Wimbledon and was awarded a PhD from Utrecht University in 2007.
Clare joined Fitzpatrick Referrals and the University of Surrey in 2013, was made a Fellow of the Royal College of Veterinary Surgeons in 2016 and awarded a Professorship of Veterinary Neurology in 2018.
Clare was made a Fellow of the Royal College of Veterinary Surgeons in 2016 in recognition of her meritorious contribution to the profession, including 25 years’ research into ‘Chiari-like malformation and syringomyelia’ in dogs.
Clare said: “I will be building and strengthening the neurology service at Wear to make it not just the leading centre in the North East, but in Europe.
“I love collaborating with others to find answers to the clinical problems we face and so, as well as potential partnership with my colleagues in the other disciplines at Wear, I hope to initiate or contribute to other multi-centre studies through the Linnaeus group.
“I am passionate about teaching and learning through collaboration, and I hope to bring multi-disciplinary rounds to the practice including neuro-radiology-neuropathology and neurology- behaviour.”
The company says that as soon as it discovered the unauthorised external access to its systems, it took them offline and started working to contain the threat.
Specialist third party consultants have been engaged to investigate the nature and extent of the incident and CVS has also informed the relevant authorities, including the Information Commissioner’s Office, because of the risk of malicious access to personal information.
The company says the majority of IT services for its practices and business functions have now been restored, but due to the increased levels of security and monitoring, some systems are not working as efficiently as before.
CVS also says that as a result of the incident, it is bringing forward plans to migrate its practice management system and related IT infrastructure to the cloud.
Analysis of the incident is ongoing and CVS says it will provide a further update in due course.
VetSurgeon member Alex Gough MRCVS, Head of Medicine Referrals at Bath Veterinary Referrals, has published his second historical thriller, Bandits of Rome, available for pre-order now in paperback (£7.99) or Kindle (£1.99) from Amazon.
The book picks up the story of Gaius Valerius Carbo as he leaves Rome with his family for the Italian countryside, only to be set upon by masked bandits.
Alex's first thriller, Watchmen of Rome, went to the top of the Amazon bestseller charts and has achieved reader reviews of an average 4.4 out of 5 stars.
Apparently the more people that pre-order the book before the 26th August, the higher it'll go up the charts. So if this sounds like it could be up your street, buy it today and you'll give a colleague a helping hand up the ladder at the same time.
A man who worked as a veterinary surgeon in Wiltshire, despite being neither qualified nor registered with RCVS, has received a 20-month sentence at Swindon Crown Court.
Peter Keniry (also known as Patrick Keniry), from Great Yarmouth, had been practising under the name of a properly qualified and legitimately registered veterinary surgeon, and was arrested on 23 August. At his initial hearing in Swindon Magistrates' Court, Mr Keniry pleaded guilty to charges of fraud by misrepresentation and unlawfully practising as a veterinary surgeon, and was released on bail.
At the Crown Court on Friday, Mr Keniry also pleaded guilty to additional charges before being sentenced. It is understood he will serve a number of months in prison, before being released on licence for the remaining period.
The RCVS assisted Wiltshire police in their apprehension of Keniry in August, having been alerted the previous day to his fraudulent activities. Mr Keniry is no stranger to the College or the police, having already been dealt with in 1998, 2001 and 2005 for similar offences. On each occasion, Mr Keniry has impersonated a member of the College whose name is legitimately on the Register, which makes it difficult even for practices that do check the credentials of prospective employees to pick up a problem.
Commenting on the recent sentencing, Gordon Hockey, RCVS Head of Professional Conduct said: "We are satisfied that the Court has clearly recognised the risk posed to both animal welfare and public safety by bogus veterinary surgeons. Anyone working as a veterinary surgeon when not qualified to do so, risks a custodial sentence.
"Mr Keniry's continued pattern of re-offending shows him to be a very convincing fraudster. By publicising his photograph, we hope to help any potential employer or locum agency reduce the chances of this happening again," he added.
The webinar, which will be streamed live at 8pm on Wednesday 20th November and will be available to watch for six months thereafter, is being presented by James Husband, an RCVS Specialist in cattle health & production.
Topics will include oxidative stress, its impact on cattle performance and the role of trace minerals in immunity and cattle health. The webinar will also cover the current complexities of oral supplementation including absorption and mineral antagonism, along with offering information about the latest innovation to boost trace mineral availability during high demand periods in the production and breeding life cycle.
To register for the webinar, visit: https://www.thewebinarvet.com/pages/register-free-role-trace-minerals-cattle-health-performance-new-veterinary-approach-boost-trace-mineral-availability/
All vets who view the webinar, either live or as a recording on the website, will be able to download a CPD certificate.
Neptra has been approved for the treatment of acute canine otitis externa or acute exacerbations of recurrent otitis caused by mixed infections of susceptible strains of bacteria sensitive to florfenicol (Staphylococcus pseudintermedius) and fungi sensitive to terbinafine (Malassezia pachydermatis), by the European Commission.
Mario Andreoli, Head of Marketing at Bayer Animal Health, said: "Otitis externa is a common disease in dogs and a leading cause why owners take their dog to a veterinarian.
"Neptra offers a key advantage, unlike competing products, it requires just one dose, administered by the veterinarian in the practice."
No at-home applications by the dog owner are required. The treatment stays in the hands of the vet who has full control over compliance.
Mario added: "With Neptra we provide a high-quality veterinary treatment that is convenient for the dog owner and ensures the well-being of dogs with a proper, effective application."
VetSurgeon understands the new product will be available in the UK in January 2020.
DogStem has been shown to be effective, reducing pain and lameness and improving mobility and quality of life for three months to over twelve months following a single injection1,2.
In a prospective, randomised, double-blinded, placebo-controlled trial of DogStem, results showed that2:
TVM highlights how DogStem simplifies the process and reduces the cost of using stem cell therapy in practice because unlike previous therapies, it does not require require a surgical harvesting procedure to be carried out under general anaesthetic.
Helen Harrison, DogStem Technical Vet and Product Manager said: "Osteoarthritis is one of the most common diseases seen in veterinary practices and is challenging to manage.
"Conventional medical treatments typically address the symptoms rather than the underlying pathological processes.
"At the same time, local treatment options that slow progression of osteoarthritis have been limited and surgical interventions aren’t always possible or may be unrewarding.
"We’re delighted to be able to offer vets DogStem®, a stem cell product with a strong evidence base across numerous mobility and quality of life parameters.’
DogStem can be ordered from NVS, or direct from: www.dogstem.co.uk
Vetswap was set up by Luke Ramsden and Euan McKee MsRCVS, two globe-trotting veterinary surgeons who saw the opportunity for colleagues in the profession to combine work and travel without losing the security of their long-term job.
As part of the partnership, VetSurgeon Jobs now includes a dedicated section for VetSwap which contains a link to job swap opportunities posted by the company.
VetSurgeon.org Editor Arlo Guthrie said: "Job swapping sounds like a great way to get a fresh-perspective and gain some CPD, not to mention a holiday in the sun.
"VetSwap is a natural fit with VetSurgeon Jobs, broadening the range of opportunities we can offer.
"On top of that, VetSurgeon.org exists to support veterinary surgeons, so when Euan and Luke contacted me, I was only too pleased to do what I can to try and give them a leg up."
VetSwap is now running a competition to win £200 worth of Amazon vouchers and a free VetSwap. All you have to do is visit their Facebook page and share this post with a colleague: https://www.facebook.com/VetSwapTM/videos/1881120178807211/
A survey published today by the veterinary recruitment agency recruit4vets has found 45.8% of salaried veterinary surgeons earning less than £35K per annum.
251 veterinary surgeons in full-time permanent employment took part in the survey, the largest number (37%) working in the south east and London.
The survey found that the typical starting salary was £31K per annum, rising to 41K for a more experienced vet in small animal practice, and £44K for more experienced large animal practitioners. The survey also found that senior vets with over 20 years experience earn up to £69K.
The survey also looked at locum charge-out rates, which varied from £220-£230 per day (17%) to over £250 (15%), with the greatest number (29%) charging between £240-£250.
62% of locums said their hourly pay rate had not changed in the last 12 months, compared to 45% of permanent staff who said their salary was unchanged over the period. This despite 65% of vets saying that the demands on them within the practice had increased in the last 12 months.
Recruit4vets has produced a couple of video presentations about the results, locum pay covered here and permanent pay covered here.
Visit VetSurgeon.org Jobs for the largest selection of classified jobs for veterinary surgeons.
Two analyses of the pet insurance market have been published this week, which together suggest that veterinary practices may be starting to price themselves out of the market.
Both reports are titled Pet Insurance 2014. In the first, published by Key Note Ltd, authors highlight a 35.4% increase in gross claims incurred on cat and dog insurance policies between 2009 and 2013, which is more than 5 times the increase in the volume of claims over the same period. It is the degree to which the value of claims has outstripped the volume which the report describes as 'undeniably the greatest factor affecting the UK market for pet insurance.
At the same time, there has been a relatively modest growth in the percentage of adults that own a cat or dog (around 1.5 percentage points). Consequently, premiums increased by 38.9% between 2009 and 2013 as insurers responded to the growing cost of claims.
Meanwhile, the other Pet Insurance 2014 report, this time from YouGov, has shown that the main factors limiting the uptake of pet insurance are poor value for money and the high cost of premiums. In 2012, 31% of owners without insurance said it was not good value for money, and that was the main reason for not taking out cover. By 2014, that figure had risen to 39% of the uninsured and 26% said they just cannot afford premiums.
According to the YouGov report, the words that uninsured pet owners most associate with pet insurance are 'expensive' (68%) and 'waste of money' (30%). Even 57% of those with insurance deem it expensive.
YouGov also highlighted that the number of uninsured pet owners who say they can afford to pay for veterinary treatment out of their own pockets (without setting money aside each month) has increased 4 percentage points from 15% in 2012 to 19% in 2014. YouGov hypothesises that this may be down to the improving economic situation in the UK, but it could equally be explained as just the way hard-pushed people self-justify their decision to discontinue insurance.
James McCoy, Research Director, YouGov Reports said: "Although social grade is important to being able to afford to take out pet insurance, our research suggests that those at different ends of the financial spectrum share the opinion that cover is not necessarily always a sound financial option.
"More affluent pet owners find insurance poor value because they can afford to pay for treatment up front; for less affluent pet owners, while pet insurance is perceived as offering good value for money, the cost of premiums is prohibitive, leading some to save money instead."
The company says that CircoMax Myco offers the longest lasting combined protection on the EU market against PCV2 and M. hyopneumoniae pathogens. This reduces the PCV2 viral load in blood and lymphoid tissues, PCV2 fecal shedding, lymphoid tissue lesions associated with PCV2 infection, and lung lesions associated with M. hyopneumoniae infections.
Pig protection was demonstrated against porcine circovirus genotypes 2a, 2b and 2d and lasts for at least 23 weeks after vaccination in fattening pigs for both PCV2 and M. hyopneumoniae.
Monica Balasch, Director, Global Biologicals Development at Zoetis, said: "Porcine circovirus type 2 has demonstrated high mutation and recombination rates and is known to be rapidly evolving in Europe and worldwide. Commercial PCV2 vaccines have been efficacious in controlling the clinical disease, but there is a growing genetic gap between field viruses and vaccines. So far, all vaccines in Europe have been based on one single genotype, PCV2a, while today the most prevalent viruses found belong to other genotypes: PCV2b and especially PCV2d.
“We believe that there is a need for new vaccines, like CircoMax Myco which includes two PCV2 genotypes for a broader coverage. We found excellent results showing reduction of body weight gain losses in field trials in the EU. This innovative one-dose vaccine is a new tool for veterinarians and producers that may improve their PCV2 and M. hyopneumoniae control programs, especially in the face of multi-genotype PCV2 infections.”
Alvaro Aldaz, Director, Global Commercial Development, Swine, Zoetis, said: "For many years, intensive vaccination has contributed to selective pressure and emergence of new PCV2 genotypes. European pig farms are often infected with more than one genotype and subclinical disease is frequent. Commercial vaccines are all based on PCV2a genotype while CircoMax Myco is the first vaccine that includes two PCV2 genotypes (a & b), and the inventive M. hyopneumoniae purified fraction. It is formulated with MetaStim for active immunization, resulting in 23 weeks of protection against these threats."
CircoMax Myco contains inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (ORF2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b ORF2 protein and inactivated Mycoplasma hyopneumoniae, strain P-5722-3.
Shockwave therapy, or Extracorporeal shockwave therapy (ESWT) to give it its full nomenclature, sends mechanical shock waves into the affected area to stimulate the natural healing process by triggering the body’s own repair mechanisms.
The therapy is being spearheaded at Willows by Kinley Smith (pictured right), an RCVS and European specialist in small animal surgery. He said: "Shockwave therapy is a whole new line of treatment and has proved a spectacular success.
"It’s an excellent technique for dealing with certain orthopaedic conditions and there’s no invasive surgery, no wound to heal and no risk of infection so it really is a win-win-win procedure.
"It is particularly effective in the treatment of ligament and tendon injuries.
"There can be immediate pain relief for the dog; after two weeks we start to see lasting benefits and in four weeks we normally see a clear improvement.
"The added bonuses are we can normally reduce any medication; the dog can enjoy more exercise plus it is not as costly as undergoing an operation.
"Surgery is still essential in some of the more acute, problematic cases but shockwave therapy has been a terrific development in helping us provide an alternative treatment in a lot of soft tissue, muscle and bone conditions."
For more information, visit www.willows.uk.net.
Vetoquinol UK Limited has launched Ceftiocyl: a ready-to-use formulation containing 50mg/ml ceftiofur for use in cattle and pigs.
In cattle, Ceftiocyl can be used for the treatment of respiratory disease, acute interdigital necrobacillosis and acute post-partum metritis. In pigs, Ceftiocyl is licensed for the treatment of respiratory disease. Ceftiocyl has the added benefit of traceability stickers which are attached to each vial making it easier and quicker to record and monitor on-farm usage.
Susan Mitchell, Large Animal Product Manager at Vetoquinol UK Ltd said, 'We are delighted to be expanding our large animal anti infective range offering. Marbocyl 10% has been used for acute mastitis in the dairy sector for many years, the addition of Ceftiocyl to our portfolio enables us to provide a cost-effective treatment for both metritis and lameness.'
1. Willshire, J.A. & Bell, N, J. (2009) An economic review of cattle lameness. Cattle Practice 17, 136-141.
The charge against Dr Irvine was that in July 2017, he failed to discuss with the owners alternative treatment options to dental surgery under general anaesthetic, or the risks of dental surgery under general anaesthetic, and failed to obtain informed consent from the owners for the surgery.
Dr Vasilev was also originally charged with failing to discuss alternative treatment options or the risks of the surgery and failing to obtain informed consent. However, at the outset of the hearing, as a result of new information which came to light, the RCVS opted to offer no evidence in relation to these charges. Mr Vasilev was separately charged with failing to maintain clear, accurate and detailed clinical records in relation to his treatment of the dog.
At the outset of the hearing, Mr Irvine denied all aspects of the charge against him; while Dr Vasilev admitted all aspects of the remaining charge.
The Committee heard how Rupert's dental surgery under general anaesthetic was recommended by Mr Irvine on 10th July and performed by Dr Vasilev on 11th July 2017. After the surgery, Rupert was discharged, but vomited in his sleep that same night. He was brought back to the practice on 12th July, where Dr Vasilev administered antiemetic and antibiotic medication.
However, Rupert continued to vomit over the next five days, and was seen by the practice on 17th July and then on 18th when blood tests were conducted. Rupert’s condition deteriorated as he continued to vomit and lose weight and he was brought back to the practice on 22nd July where he was euthanased by Dr Vasilev.
The Committee heard evidence from Rupert’s owners as well as two expert witnesses. It found the first aspect of the charge against Mr Irvine proven on the basis that there was an inadequate discussion with the owners regarding the option of delaying the dental treatment on Rupert because of his recent ascites caused by congestive heart failure.
The Committee found the second aspect of the charge against Mr Irvine proven on the basis that he had not discussed the risks of Rupert undergoing general anaesthetic given the recent diagnosis of congestive heart failure, following which (in relation to the third aspect of the charge against Mr Irvine), it was therefore found proven that he had failed to gain informed consent.
With all aspects of the charge against Mr Irvine being proven, and with Dr Vasilev admitting the charge against him, the Committee went on to consider if the proven and admitted charges against both amounted to serious professional misconduct.
In respect of Mr Irvine, Stuart Drummond, chairing the Committee and speaking on its behalf, said: "The Committee was not persuaded that the failure to obtain informed consent from [the owner] and discuss matters further with her on 10th July 2017 in the circumstances of this case would amount to serious professional misconduct which would bring the profession into disrepute.
"In the Committee’s judgment, the breach of standards, whilst amounting to professional misconduct, was not serious professional misconduct, in the context of other discussions which had taken place…. The Committee further decided that a finding of serious professional misconduct in this case would be disproportionate having taken into consideration the discussions that Mr Irvine had with [the owner] prior to 10th July 2017 and the fact he was dealing with a complex and changing case.
"The Committee therefore found that Mr Irvine was not guilty of disgraceful conduct in a professional respect."
The Committee noted that Dr Vasilev had admitted breaching the Code of Professional Conduct for Veterinary Surgeons in respect of failing to keep adequate clinical and client records.
However, in mitigation, the Committee considered a number of factors including that, in failing to maintain adequate notes related to Rupert’s treatment, Dr Vasilev had followed the standard of notetaking in the practice as set out by Mr Irvine who was practice principal; that Dr Vasilev had only worked with Mr Irvine in the UK and his record-keeping was limited to working in one practice; that Dr Vasilev admitted his failures at an early stage of the proceedings; that he had made efforts to avoid repetition in the future by undertaking webinars and research; and, that he had shown insight into the need to ensure full communication and detailed note-taking.
Stuart Drummond added: "In relation to Dr Vasilev, the Committee was satisfied that [his] standard of record-keeping was in breach of the Code of Professional Conduct for Veterinary Surgeons and that the breach… amounted to professional misconduct.
"The Committee concluded that the breaches overall, when considering the context and number of mitigating factors, were, in the Committee’s view, insufficient to amount to serious professional misconduct…. Accordingly it found Dr Vasilev not guilty of disgraceful conduct in a professional respect."
The full facts and findings from the case can be found at www.rcvs.org.uk/disciplinary.
Intervet/Schering-Plough Animal Health is to launch CICADA-Live, the second phase of its national initiative to monitor the awareness and regional prevalence of important diseases in cats, dogs and rabbits.
First launched in 2007 as a quarterly survey, the ground-breaking CICADA-Live project has now been developed to offer up-to-the minute data on infectious companion animal disease reports that can be updated and accessed by vet practices around the clock. The new scheme is now able to provide a real-time overview of companion animal infectious diseases being diagnosed in UK veterinary practices.
CICADA-Live is focusing on more than a dozen key infectious diseases of dogs, cats and rabbits. They include canine parvovirus, infectious canine hepatitis, canine distemper, leptospirosis, kennel cough, angiostrongylosis. For cats, CICADA-Live will monitor feline panleucopaenia, cat flu, feline leukaemia virus infections. For rabbits the focus will be on myxomatosis, rabbit viral haemorrhagic disease, E.cuniculi, and fly strike.
The service is officially launched on 1st June to coincide with Intervet/Schering-Plough Animal Health's National Vaccination Month 2009, and is open to all first-opinion UK companion animal veterinary practices.
The system's developer, John Helps, Veterinary Manager at Intervet/Schering-Plough Animal Health said: "Whereas our first edition of CICADA was useful in providing benchmarks so that seasonal and long term trends could be identified and communicated to both vets and pet owners, the further potential of a live on-line database is enormous in raising awareness of current pet disease risks to the public."
According to the company, there has been a lack of knowledge regarding the local and national incidence of small animal infectious diseases in the UK, and those sporadic reports that do occur are typically anecdotal and can prove hard to substantiate. It is feared that the lack of co-ordinated good quality information has potentially lead to pet owners being lulled into a false sense of security by a low awareness of disease risks.
John added: "Lack of data on the incidence and prevalence of even the most common infectious diseases has been an important issue faced by small animal practices reducing their ability to highlight these risks. A staggering lack of owner awareness to infectious disease threats in turn contributes to complacency among pet owners.
"Evidence suggests that some infectious diseases, such as parvovirus, may be on the increase in some areas and there continues to be a concern regarding the number of animals that remain unvaccinated.
"Not only will Cicada-Live provide the means for improving a gap in our collective knowledge but it will also prove invaluable in the promotion of good preventative healthcare.
"We have long believed that better epidemiological surveillance would an important tool in understanding trends in small animal infectious disease and with CICADA-Live, for the first time we have a tool to give us a better appreciation of what first opinion practices are currently seeing."
The CICADA-Live website, http://www.cicadasurvey.co.uk/, is simple to access and update. Registrations are limited to one per practice branch. A straightforward one-page survey format minimises the time investment, with no strict requirement to review written case records.
Once signed in, participating practices will be asked to complete the survey once every 6 months in order to grant continued access to maps and tables showing recent reports. In addition practices can set up e-mail alerts to give notification should disease reports be received in their area.
For further information about CICADA-Live from Intervet please contact Intervet /Schering-Plough Animal Health's Veterinary Support Group on 01908 685685. Or contact John.
The tool is available to all practices, free of charge.
The downloadable and printable guide chart, which has been created by a number of specialists, will help veterinary surgeons, nurses and receptionists to identify urgent, potentially urgent, non-urgent and delayable cases to help limited veterinary resources be used to best efficiency without compromise to animal health or welfare.
The chart, which can be printed and put on a practice wall or referred to as a webpage via a mobile phone or tablet, has a number of supporting resources produced by the same specialists.
Sue Paterson, BSAVA President, said: “During these exceptional and worrying times veterinary surgeons need as much practical help and support as possible.
"We are hugely grateful for the indefatigable support of an enthusiastic group of volunteers who have rapidly produced this triage tool, which we are now able to share. It should enable patient queries to be processed, reliably and efficiently, allowing for emergency patients to be seen as a matter of urgency, within the current government and RCVS guidelines."
The triage tool is free to download and share: https://www.bsava.com/TriageTool
BSAVA is working on a number of other initiatives to support veterinary professionals during the current crisis, including new guidance on obtaining consent remotely for veterinary treatment. for more information, visit: https://www.bsava.com/adviceforCOVID19
Mr Wood was convicted of three offences which involved the download of 38 videos and 13 indecent images of children, at Portsmouth Magistrates’ Court in December 2017.
In January 2018, he was sentenced to a three-year Community Sentence for each offence, to run concurrently, and was made subject to a five-year Sexual Harm Prevention Order.
He was also fined £1,000 and ordered to pay costs of £340 and a victim surcharge of £85.
Mr Wood was also placed on the barring list by the Disclosure and Barring Service and required to register with the police pursuant to the Sexual Offences Act 2003 for a period of five years.
Mr Wood appeared before the Disciplinary Committee, admitted his conviction and accepted that it rendered him unfit to practise veterinary surgery.
In determining the sanction, the Committee says it took into account a number of mitigating factors: his conviction involved no actual harm or risk of harm to an animal; there was no financial gain; he had engaged in open and frank admissions at an early stage; he was experiencing mental ill-health at the time of the offence; he had taken subsequent steps to avoid a repetition of such behaviour; there had been a significant lapse of time since the incident; and he showed insight into the harm caused by his offence.
The Committee also considered that the purpose of a sanction is not to punish, but to protect the welfare of animals, as well as maintain public confidence in the profession and declare and uphold proper standards of conduct. On consideration of the appropriate sanction, the Committee decided that postponement of judgement was not appropriate, and that taking no action was not an option.
The Committee then considered whether a reprimand or warning was appropriate, but they considered that would not match the gravity of the offence – a period of suspension would also mean Mr Wood would automatically return to the Register after the period of time without the College being able to review his fitness to practise, rendering it an inappropriate sanction. The Committee therefore determined that the removal of Mr Wood from the RCVS Register was the only way to protect the wider public interest and maintain confidence in the profession.
Ian Green, chairing the Committee and speaking on its behalf, said: "The Committee has not taken this decision lightly, and, lest it be misinterpreted, it has not taken it in order to satisfy any notional public demand for blame and punishment.
"It has taken the decision because in its perception, the reputation of the profession had to be at the forefront of its thinking and ultimately it was more important than the interests of the Respondent.
"The decision is not simply based on the fact that these offences were of a sexual nature but because they were repeated frequently over a significant period of time, and at the time, the Respondent knew on his own admission that what he was doing was wrong.
"Accordingly, the Committee had decided that removal from the Register is appropriate and proportionate in this case. The Committee will direct the Registrar to remove the Respondent’s name from the Register forthwith."
Mr Wood has 28 days to appeal the Committee’s decision after which, if no appeal is received, the Committee’s judgment takes effect.
The aim of the competition is to highlight top tips for pet owners and the benefits of building a den to help calm and reassure dogs during the fireworks festivities.
Practices that want to take part in the in the competition need to post pictures of their dens and waiting rooms on the Ceva Animal Health Facebook page in October. The winning practice will receive a £200 voucher and there are 10 runner up prizes of luxury chocolate hampers.
Abigail King, behaviour product manager at Ceva Animal Health, said: "Our hugely popular fireworks display competition encourages veterinary practices to create eye-catching and imaginative displays that help educate pet owners on what can be done at home to help calm and reassure pets with firework fears."
Ceva has a range of marketing materials for veterinary practices to use in the competition, including waiting room materials.
For further information, contact your Ceva territory manager.
Medivet has reported a wide range of public reaction to the recent Panorama programme 'It shouldn't happen at a vets', most of which has been at one extreme or the other.
On the one hand, says the company, many clients have gone out of their way to show their support, whilst on the other, staff have faced considerable anger from members of the public (not known to be Medivet clients).
After transmission, staff at a handful of practices received abusive comments and threatening behaviour. The day after transmission, a veterinary nurse in uniform who was not shown in the programme was called 'dog beater' in the street in Oxford, leaving her feeling very shaken. Staff from other branches have received similar treatment when out in uniform; Medivet recommended that its staff cover up their uniforms when outdoors, and has been working with the Metropolitan Police and other forces.
Two individuals named in the film - Arnold Levy, Medivet's managing partner, and a veterinary nurse who was shown admitting to having struck a dog - received emailed death threats. The nurse has since resigned.
At practices, a receptionist was sworn at, several received abusive phone calls and one of Medivet's kennel staff in Oxted, Surrey was woken in the early hours one morning by people banging on the doors and shouting abuse. Most incidents occurred within the first 48 hours following the programme.
In contrast, Medivet says several practices have been overwhelmed by the level of support shown to staff by clients. Some have brought in gifts of flowers, biscuits and chocolates, and one client visited his practice specifically to tell staff of his and his wife's support.
Staff and managers have received many supportive emails, cards, letters and verbal comments contrasting between the picture portrayed by the programme and their personal experience of Medivet and the level of care their pets receive.
Medivet says that discussions with clients about the programme have been balanced, with many appreciating that the programme was not made in a balanced or fair way. The company also says it believes that, in the vast majority of cases, the strength of the relationship of trust between clients and the teams that look after their pets has not been undermined.
The survey, which this year had a record 1605 respondents, covers everything from basic earnings, bonuses and dividends to benefits such as accommodation, car allowance and pensions.
The survey found that the median salary package for all vets in 2021 was £48,325; £3000 more than in 2020.
For all nurses the median package was £24,227 in 2021 and for head nurses the figure rose to £31,013.
The median daily rate for a locum vet was £350 in 2021, a rise of over 16% since 2020.
The hourly locum rate increased by 36% to £41 per hour.
Similarly, locum nurse daily rates have risen by over 30% since 2020 to £144 and their hourly rate increased by 14% to £20.
New grad vets' salary packages actually dropped by £800 in 2021, to £32,700.
However, the 2021 new grad hourly rate increased to £15.66 from £15.04 in 2020.
SPVS says this could indicate that newly qualified vets are earning less because they are working, on average, three hours less a week.
This may suggest that they are prioritising their work life balance, with time off being more important than an overall salary.
SPVS also highlights a growing gender gap in salary.
81% of the respondents were female, and the median full time salary difference between men and women was 21%, compared to 15% in 2020.
SPVS hypothesises that this could be because there are more male vets in more senior positions, rather than because of gender per se.
The question, therefore, is why there are more male vets than females in senior positions.
The survey showed very similar numbers of males and females doing both clinical and non-clinical post graduate training. But more than twice as many men than women go on to take up positions of leadership or seniority, or in referrals.
More research is needed to understand why females are doing the extra training, but apparently not using it to further their career.
As in 2020 SPVS has also looked at satisfaction with remuneration, hours worked, conditions, support and prospects and is using this data to create a separate report which will be available soon.
For more information, visit: https://spvs.org.uk/spvs-survey/
55 veterinary surgeons took part in the survey, which also found that only 37% of clinicians use FNA and cytology when investigating a suspected lipoma.
According to the survey, the biggest barriers to further investigations of lumps and bumps were cost (50%), short consult time (23%) and confidence in results (20%).
HT Vista, which earlier this year launched a cancer screening device for dogs which uses heat diffusion technology and AI to differentiate between benign skin masses and other tumours, is urging more practising vets to use an accurate screening process for early detection of malignant masses.
Dr. Gillian Dank, Board Certified Oncologist and Chief Veterinary Officer at HTVet, said: “There is no way to know that a mass is a lipoma based on palpation alone.
"The fact that a mass is subcutaneous, soft and circumscribed is not exclusive to lipoma and it could be a number of things including a mast cell tumour or sarcoma.
"On average a veterinary practice sees over 500 dermal and subcutaneous masses each year.
"We know anecdotally, and surveys like this confirm, that not every mass is aspirated – and that is why there is need for the HT Vista screening device.
"Every mass that comes in should be properly examined.”
“It’s interesting to see that the more experienced a clinician is, the less confident they are in diagnosing from palpation and this shows us that with experience we understand that our hands are not enough.”
Liron Levy-Hirsch, Managing Director of HT Vista, said: “The survey showed that vets are conscious of the cost to clients, and also feel pressured due to time.
"We have developed the HT Vista to complement FNA and cytology, and hope clinicians find it a useful tool.
"Firstly, it is quick and affordable to scan, and for those masses that are benign it removes the need for unnecessary FNA’s.
"Secondly, vets are often wary of cost, however if a mass is scanned and the results indicate that further investigation is needed, there is more rationale to spend the extra money to get the cytology results.
"Finally, the device can offer complete confidence that malignancies are not being missed, and if a mass is malignant a prompt treatment plan can be initiated.”
https://www.vetreport.net/wp-content/uploads/2023/08/Lump-and-Bump-Survey-2023FINAL.pdf
https://ht-vista.uk